Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8832 |
High Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.8832 |
High Similarity |
NPD5124 |
Phase 1 |
0.875 |
High Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.8732 |
High Similarity |
NPD3750 |
Approved |
0.8657 |
High Similarity |
NPD2797 |
Approved |
0.8649 |
High Similarity |
NPD7411 |
Suspended |
0.8621 |
High Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8621 |
High Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.8582 |
High Similarity |
NPD3225 |
Approved |
0.8531 |
High Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.8511 |
High Similarity |
NPD3748 |
Approved |
0.8496 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.8478 |
Intermediate Similarity |
NPD3268 |
Approved |
0.8421 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.8344 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.8289 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.8289 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8264 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8264 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8255 |
Intermediate Similarity |
NPD5403 |
Approved |
0.8252 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.8247 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.8219 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.8214 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.8214 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8207 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8194 |
Intermediate Similarity |
NPD2796 |
Approved |
0.8176 |
Intermediate Similarity |
NPD6799 |
Approved |
0.8158 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.8125 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.8125 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8121 |
Intermediate Similarity |
NPD5401 |
Approved |
0.8117 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8116 |
Intermediate Similarity |
NPD3267 |
Approved |
0.8116 |
Intermediate Similarity |
NPD3266 |
Approved |
0.8099 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8092 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.8071 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8069 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.8069 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.806 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8052 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.805 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.8027 |
Intermediate Similarity |
NPD1243 |
Approved |
0.8013 |
Intermediate Similarity |
NPD3749 |
Approved |
0.8012 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.8 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7986 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7986 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7974 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7972 |
Intermediate Similarity |
NPD4307 |
Phase 2 |
0.7959 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7958 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7958 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7949 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7943 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7899 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7898 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7895 |
Intermediate Similarity |
NPD920 |
Approved |
0.7885 |
Intermediate Similarity |
NPD4288 |
Approved |
0.7885 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7885 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7867 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7852 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7826 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7821 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7817 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7815 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7791 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.777 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7763 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7763 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7762 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7756 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7744 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7733 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7733 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7712 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7703 |
Intermediate Similarity |
NPD4476 |
Approved |
0.7703 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7703 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7703 |
Intermediate Similarity |
NPD4477 |
Approved |
0.7702 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7677 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7677 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7671 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7664 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7655 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7647 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7647 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7647 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7643 |
Intermediate Similarity |
NPD1481 |
Phase 2 |
0.764 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7595 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7595 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7593 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.759 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7586 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7582 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7576 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7571 |
Intermediate Similarity |
NPD1535 |
Discovery |
0.7562 |
Intermediate Similarity |
NPD6971 |
Discontinued |
0.7561 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7554 |
Intermediate Similarity |
NPD17 |
Approved |
0.755 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7545 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7535 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7533 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7533 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7533 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7533 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7533 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7533 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD919 |
Approved |
0.7516 |
Intermediate Similarity |
NPD6502 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.75 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6651 |
Approved |
0.75 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7484 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7484 |
Intermediate Similarity |
NPD5049 |
Phase 3 |
0.7483 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.747 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7469 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7465 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7452 |
Intermediate Similarity |
NPD8158 |
Clinical (unspecified phase) |
0.7452 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.745 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7448 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7436 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7432 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7432 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7432 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7431 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7429 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7426 |
Intermediate Similarity |
NPD1241 |
Discontinued |
0.7425 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7425 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7423 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7421 |
Intermediate Similarity |
NPD37 |
Approved |
0.7417 |
Intermediate Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.7415 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.741 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.741 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7403 |
Intermediate Similarity |
NPD6667 |
Approved |
0.7403 |
Intermediate Similarity |
NPD6666 |
Approved |
0.7397 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7396 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7396 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7391 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7391 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7381 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7381 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7379 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7365 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7355 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7355 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7347 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7347 |
Intermediate Similarity |
NPD411 |
Approved |
0.7337 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7333 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD2614 |
Approved |
0.7325 |
Intermediate Similarity |
NPD7427 |
Discontinued |
0.7324 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7324 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7315 |
Intermediate Similarity |
NPD447 |
Suspended |
0.731 |
Intermediate Similarity |
NPD1019 |
Discontinued |
0.7308 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7305 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7301 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7296 |
Intermediate Similarity |
NPD6585 |
Discontinued |
0.7294 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.729 |
Intermediate Similarity |
NPD7440 |
Discontinued |
0.7289 |
Intermediate Similarity |
NPD7784 |
Clinical (unspecified phase) |
0.7288 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7266 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7255 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7254 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.725 |
Intermediate Similarity |
NPD5889 |
Approved |
0.725 |
Intermediate Similarity |
NPD5890 |
Approved |
0.7248 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7237 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7237 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7237 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7237 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7234 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7226 |
Intermediate Similarity |
NPD2354 |
Approved |
0.7218 |
Intermediate Similarity |
NPD9697 |
Approved |
0.7202 |
Intermediate Similarity |
NPD5940 |
Clinical (unspecified phase) |
0.7202 |
Intermediate Similarity |
NPD7177 |
Discontinued |
0.72 |
Intermediate Similarity |
NPD4622 |
Approved |
0.72 |
Intermediate Similarity |
NPD4618 |
Approved |
0.72 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7193
|
Intermediate Similarity |
NPD7549 |
Discontinued |